Research programme: RNAi therapeutics - Arbutus

Drug Profile

Research programme: RNAi therapeutics - Arbutus

Alternative Names: AB 729; ARB 270729; LNP-siRNA therapeutics - Arbutus; TKM-ALDH; TKM-GSD; TKM-HTG; TKM-Marburg; WEE1/CSN5

Latest Information Update: 16 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protiva Biotherapeutics
  • Developer Arbutus Biopharma
  • Class Small interfering RNA
  • Mechanism of Action COPS5 protein inhibitors; RNA interference; WEE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alcoholism; Marburg virus disease; Metabolic disorders

Highest Development Phases

  • Preclinical Hepatitis B
  • Suspended Alcoholism; Hypertriglyceridaemia; Marburg virus disease; Non-alcoholic steatohepatitis; Solid tumours
  • No development reported Lysosomal-storage diseases

Most Recent Events

  • 07 Nov 2018 Arbutus Biopharma plans a clinical trial for AB 729 in Hepatitis B in the second quarter of 2019
  • 07 Nov 2018 Arbutus Biopharma plans clinical combination studies of AB 729 in Hepatitis B in the second quarter of 2019
  • 03 May 2018 Arbutus Biopharma intends to submit IND/CTA-regulatory filing for AB 729 in late-2018 or early-2019 to enable the initiation of a phase I trial in Hepatitis B
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top